We’re excited to announce that Oruka Therapeutics has joined the International Psoriasis Council as a 2025 Bronze Level Corporate Member. Oruka is a pioneering biopharmaceutical company advancing potentially best-in-class monoclonal antibody therapies for plaque psoriasis, psoriatic arthritis, and related inflammatory skin conditions. Their seasoned team of biopharma professionals is dedicated to improving patient experiences through innovative biologic treatments.
“We’re delighted to welcome Oruka into the IPC community,” said IPC CEO Christy Langan. “Their focus on developing targeted antibody therapies will deepen our collective understanding of psoriasis biology and support our goal of improving care for people living with this disease.”
Please join us in extending a warm welcome to Oruka.
